References
- Normanno N, Apostolidis K, Wolf A, et al. Access and quality of biomarker testing for precision oncology in Europe. Eur J Cancer. 2022;176:70–77.
- Seth R, Messersmith H, Kaur V, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Oncol. 2020;38(33):3947–3970.
- Gennari A, Andre F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–1495.
- Cervantes A, Adam R, Rosello S, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32.
- Ou FS, Michiels S, Shyr Y, et al. Biomarker discovery and validation: statistical considerations. J Thorac Oncol. 2021;16(4):537–545.
- Nakayasu ES, Gritsenko M, Piehowski PD, et al. Tutorial: best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation. Nat Protoc. 2021;16(8):3737–3760.
- Wang S, Li W, Hu L, et al. NAguideR: performing and prioritizing missing value imputations for consistent bottom-up proteomic analyses. Nucleic Acids Res. 2020;48(14):e83.
- Lualdi M, Fasano M. Statistical analysis of proteomics data: a review on feature selection. J Proteomics. 2019;198:18–26.
- Diaz-Uriarte R, Gomez de Lope E, Giugno R, et al. Ten quick tips for biomarker discovery and validation analyses using machine learning. PLoS Comput Biol. 2022;18(8):e1010357.
- Briukhovetska D, Dorr J, Endres S, et al. Interleukins in cancer: from biology to therapy. Nat Rev Cancer. 2021;21(8):481–499.
- Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40(16):1816–1837.
- Hendrix SB, Mogg R, Wang SJ, et al. Perspectives on statistical strategies for the regulatory biomarker qualification process. Biomark Med. 2021;15(9):669–684.
- Sarhadi VK, Armengol G. Molecular biomarkers in cancer. Biomolecules. 2022;12:8.
- Ng K, Stenzl A, Sharma A, et al. Urinary biomarkers in bladder cancer: a review of the current landscape and future directions. Urol Oncol. 2021;39(1):41–51.
- Mischak H, Ioannidis JP, Argiles A, et al. Implementation of proteomic biomarkers: making it work. Eur J Clin Invest. 2012;42(9):1027–1036.